Stock Analysis
Gufic Biosciences Full Year 2024 Earnings: EPS: ₹8.74 (vs ₹8.22 in FY 2023)
Gufic Biosciences (NSE:GUFICBIO) Full Year 2024 Results
Key Financial Results
- Revenue: ₹8.09b (up 17% from FY 2023).
- Net income: ₹861.4m (up 8.1% from FY 2023).
- Profit margin: 11% (in line with FY 2023).
- EPS: ₹8.74 (up from ₹8.22 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Gufic Biosciences shares are down 9.0% from a week ago.
Risk Analysis
You should learn about the 3 warning signs we've spotted with Gufic Biosciences (including 2 which are potentially serious).
Valuation is complex, but we're helping make it simple.
Find out whether Gufic Biosciences is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:GUFICBIO
Gufic Biosciences
Manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally.
Adequate balance sheet and overvalued.